Flaherty et al. also indicated that metastatic melanomas resistant to BRAF inhibitors still require MAPK activity and that combined use of BRAF and MEK inhibitors demonstrated a significant increase in median progression-free survival (PFS) compared to BRAF monotherapy [30, 31]. This evidence concerns the gene BRAF and metastatic melanoma.